Please assess the completion status of the following clinical trial:

Trial Title: Omega-3 Fatty Acids Supplementation Improves Early-stage Diabetic Nephropathy and Subclinical Atherosclerosis in Pediatric Patients With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with T1DM on regular insulin therapy.~* age from 12 to 18 years.~* disease duration at least 5 years.~* having diabetic nephropathy in the form of microalbuminuria (urinary albumin excretion \[UAE\] 30-299 mg/g creatinine).~* hemoglobin A1c (HbA1c) ≤8.5% (69 mmol/mol).~* persistent microalbuminuria was confirmed by abnormal two or three urine samples over a 3- to 6-months period prior to the study despite angiotensin converting enzyme inhibitors (ACE-Is)~Exclusion Criteria:~* patients with any clinical evidence of infection.~* patients with renal impairment due to causes other than diabetes.~* other diabetic complications than nephropathy.~* elevated liver enzymes.~* hyper- or hypo-thyroidism.~* intake of any vitamins or food supplements one month before study.~* participation in a previous investigational drug study within the three months preceding screening.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- oral omega-3 fatty acids supplementation (Type: ACTIVE_COMPARATOR): Intervention group included pediatric patients with diabetic nephropathy receiving oral omega-3 fatty acids supplementation on a daily basis.
- Placebo comparator (Type: PLACEBO_COMPARATOR): Placebo group or control patients received placebo that were similar in appearance to omega 3 fatty acids and the administered dose was as the same schedule as omega 3 fatty acids.

Based on this trial design, predict the completion outcome and termination type (if applicable).